John E. Imhoff - Jul 17, 2023 Form 4 Insider Report for GUIDED THERAPEUTICS INC (GTHP)

Role
Director, 10%+ Owner
Signature
/s/ John E. Imhoff
Stock symbol
GTHP
Transactions as of
Jul 17, 2023
Transactions value $
$0
Form type
4
Date filed
9/7/2023, 04:53 PM
Previous filing
Jun 26, 2023
Next filing
Feb 22, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GTHP Common Stock Other +26.3K +0.6% 4.44M Jul 17, 2023 Direct F1
transaction GTHP Common Stock Purchase +501K +11.29% 4.94M Aug 11, 2023 Direct F2
transaction GTHP Common Stock Other +113K +2.28% 5.05M Aug 21, 2023 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GTHP Series E Preferred Stock Purchase +250 250 Aug 11, 2023 Common Stock 1M $0.25 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.2139.
F2 These shares were issued as part of Common Stock Purchase Agreement signed between Dr. Imhoff and Rosalind Master Fund, LLP, on August 3, 2023. For a price of $150,090, Dr. Imhoff purchased 500,899 shares of Guided Therapeutics' (GTHP) common stock, par value $0.001 and 250 shares of GTHP Series E Convertible Preferred Stock (see (3)).
F3 These securities consist of Series E Convertible Preferred Stock ("Series E Preferred") of the Issuer that are presently convertible on a 1-for-4,000 basis into Common Stock without payment or further consideration. The Series E Preferred shares are convertible at any time until 8/21/2025. The Series E Preferred has no expiration date.
F4 These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.1777.